Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Report Date: August 13, 2026
Reporting Period: Second Quarter ended June 30, 2026
Business Overview: The Company is a Delaware corporation focused on therapeutic development, with principal executive offices in San Diego, California. This filing announces the release of financial results for the quarter ended June 30, 2026.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the detailed financial results but does not include the specific numerical data within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only confirms the issuance of a press release titled "Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update."
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that a corporate update was provided alongside the financial results in the attached press release, but the content of this update is not included in the text provided.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt. The filing includes a standard disclaimer that the information furnished under Item 2.02 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for specific revenue, net loss, and cash position figures for Q2 2026.
- Verify the "Corporate Update" section in the press release for any changes in clinical trial timelines or regulatory milestones.
- Check the Company's cash runway and burn rate as disclosed in the full financial statements referenced by this 8-K.
- Confirm if any new debt financing or equity raises were announced in the full press release to address liquidity needs.